Drugs / Pneumococcal Vaccine, Polyvalent (23-valent)

Trials 3 · a red edge is where a trial was stopped

20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 31 trial
Phase 3 NCT00496093 Oct 2005 → Jan 2006 pneumococcal infection Merck Sharp & Dohme LLC Completed No outcome recorded
Phase not applicable2 trials
NCT00001080 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Withdrawn No outcome recorded
NCT00013871 ? → Nov 2004 HIV infectious disease, hepatitis B virus infection, measles, pertussis +1 National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00000829 Background ? → Oct 1999 HIV infectious disease, pneumococcal infection National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase not applicable1 trial
NCT00034086 Background ? → Jun 2006 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as Pneumococcal Vaccine, Polyvalent (23-valent) ClinicalTrials.gov intervention name — accepted as the source's own label NCT00496093
4

NCT00013871

NCT00000829

NCT00034086

NCT00001080

Known as PNU-IMUNE 23 “Additionally, patients receive PNU-IMUNE 23 ( pneumococcal polyvalent vaccine ) at 24 months of age.” NCT00000829
Modality Vaccine “pneumococcal polyvalent vaccineNCT00000829
Route Intramuscular “by intramuscular (deltoid) injection” NCT00496093